Drugs / 68Ga-HBED-CC-PSMA
68Ga-HBED-CC-PSMA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04243941 | Nov 2022 → Feb 2024 | prostate cancer | UNC Lineberger Comprehensive Cancer Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT02810886 | Oct 2016 → Jan 2017 | prostate cancer | Jules Bordet Institute | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03001869 | Jul 2017 → Jul 2023 | prostate cancer | Sir Mortimer B. Davis - Jewish General Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-(HBED-CC)-PSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02810886 ↗ |
| Known as | 68Ga-PSMA | “A radiotracer in use today is 68Ga-HBED-CC-PSMA (DKFZ-11) - hereinafter abbreviated 68Ga-PSMA - which is a radiolabeled urea-based ligand for prostate specific membrane antigen...” NCT03001869 ↗ |
| Known as | DKFZ-11 | “A radiotracer in use today is 68Ga-HBED-CC-PSMA (DKFZ-11) - hereinafter abbreviated 68Ga-PSMA - which is a radiolabeled urea-based ligand for prostate specific membrane antigen...” NCT03001869 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga-PSMA-ligand PET-CT is a recently developed molecular imaging technique.” NCT02810886 ↗ |
| Route | Intravenous | “68Ga-PSMA-ligand intravenous administration duration is around one minute.” NCT02810886 ↗ |